Trial on Metoclopramide and Ketoprofen in Acute Migraine of Childhood
Launched by IRCCS BURLO GAROFOLO · Nov 13, 2007
Trial Information
Current as of April 29, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children 6-17 years old with migraine presenting in emergency room
- Exclusion Criteria:
- • Informed consensus not obtained
- • Occurring migraine still treated
- • Hemiplegic migraine
About Irccs Burlo Garofolo
IRCCS Burlo Garofolo is a prestigious research institute located in Trieste, Italy, dedicated to advancing pediatric healthcare through innovative clinical research. As a recognized IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it focuses on a wide range of pediatric diseases, emphasizing the integration of clinical care and scientific research to improve patient outcomes. The institute collaborates with various national and international partners, fostering an environment of rigorous scientific inquiry and excellence in medical practice. Its commitment to ethical standards and patient safety ensures that all clinical trials conducted under its auspices contribute meaningful advancements in pediatric medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Trieste, , Italy
Patients applied
Trial Officials
Edoardo Guglia, MD
Principal Investigator
IRCCS Burlo Garofolo
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials